Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CHA2DS2-VASc score

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    22 result(s) found for: CHA2DS2-VASc score. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2022-000758-28 Sponsor Protocol Number: 19767 Start Date*: 2022-11-23
    Sponsor Name:Bayer AG
    Full Title: A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibito...
    Medical condition: Prevention of stroke or systemic embolism in atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10049165 Cerebrovascular accident prophylaxis PT
    21.1 10042613 - Surgical and medical procedures 10049910 Thromboembolism prophylaxis LLT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned) DE (Trial now transitioned) BE (Trial now transitioned) FI (Trial now transitioned) AT (Trial now transitioned) ES (Trial now transitioned) SE (Trial now transitioned) HU (Trial now transitioned) NO (Trial now transitioned) SK (Trial now transitioned) LT (Trial now transitioned) CZ (Trial now transitioned) NL (Trial now transitioned) GR (Trial now transitioned) IT (Trial now transitioned) LV (Trial now transitioned) PT (Trial now transitioned) PL (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002365-35 Sponsor Protocol Number: 19765 Start Date*: 2020-01-24
    Sponsor Name:Bayer AG
    Full Title: Multicenter, randomized, active comparator-controlled, double-blind, double-dummy, parallel group, dose-finding Phase 2 study to compare the safety of the oral FXIa inhibitor BAY 2433334 to apixaba...
    Medical condition: Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10053468 Anticoagulant therapy PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) NL (Completed) FR (Completed) GB (GB - no longer in EU/EEA) HU (Completed) BE (Completed) LV (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2018-001013-32 Sponsor Protocol Number: CV-185-685 Start Date*: 2018-11-08
    Sponsor Name:HOSPITAL CLÍNIC BARCELONA
    Full Title: ANTITHROMBOTIC THERAPY AFTER LEFT ATRIAL APPENDAGE OCCLUSION: DOUBLE ANTIPLATELET THERAPY VS. APIXABAN
    Medical condition: ATRIAL FIBRILLATION IN PATIENTS AFTER OCCLUSION OF THE LEFT ATRIAL APPENDAGE (LAAC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002075-33 Sponsor Protocol Number: ENRICH-AF Start Date*: 2020-05-05
    Sponsor Name:Hamilton Health Sciences, through its Population Health Research Institute
    Full Title: Edoxaban for intracranial hemorrhage survivors with atrial fibrillation
    Medical condition: High risk atrial fibrillation patients with previous intracranial hemorrhage
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10018985 Haemorrhage intracranial PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) NO (Prematurely Ended) DE (Trial now transitioned) ES (Ongoing) PT (Trial now transitioned) BE (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) DK (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-000721-11 Sponsor Protocol Number: CHPAU2019/03 Start Date*: 2020-09-24
    Sponsor Name:Centre hospitalier de PAU
    Full Title: Management of Anticoagulant Therapy monitored by an implantable device with telecardiology in patients with Acute Coronary Syndrome associated with de novo atrial Fibrillation Arrhythmia (SCA-FA): ...
    Medical condition: acute coronary syndrome and atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-000503-40 Sponsor Protocol Number: GE IDE No. A01611 Start Date*: 2011-04-12
    Sponsor Name:Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen
    Full Title: DABI-ADP-1: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION
    Medical condition: Patients with atrial fibrillation and an indication for oral anticoagulation.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-005364-26 Sponsor Protocol Number: RE-LATED-AF Start Date*: 2014-07-17
    Sponsor Name:University Medical Center of the Johannes Gutenberg University Mainz
    Full Title: Resolution of Left Atrial-Appendage Thrombus – Effects of Dabigatran in patients with AF (RE-LATED AF) – A Prospective, multicenter, randomized, open-label, controlled, explorative, blinded-endpoin...
    Medical condition: Left atrial-appendage thrombus in atrial fibrillation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-005109-19 Sponsor Protocol Number: ATTICUS Start Date*: 2015-11-10
    Sponsor Name:University Hospital Tuebingen
    Full Title: Apixaban for treatment of embolic stroke of undetermined source
    Medical condition: Patients with embolic stroke of undetermined source and at least on risk factor for cardiac embolism
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-002741-29 Sponsor Protocol Number: CMAA868A2202 Start Date*: 2018-05-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A multicenter, randomized, open-label, active-controlled, dose-range finding study to assess the pharmacodynamic parameters, safety and tolerability of MAA868 and its effect on thrombogenesis bioma...
    Medical condition: atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Suspended by CA) SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002176-41 Sponsor Protocol Number: 17HH4268 Start Date*: 2019-09-03
    Sponsor Name:Imperial College of Science Technology and Medicine
    Full Title: PREvention of STroke in Intracerebral haemorrhaGE survivors with Atrial Fibrillation (PRESTIGE-AF)
    Medical condition: Ischaemic stroke prevention in patients with atrial fibrillation and previous intracerebral haemorrhage
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    20.0 100000004849 10034039 Paroxysmal atrial fibrillation LLT
    20.0 100000004849 10066551 Chronic atrial fibrillation LLT
    20.0 100000004849 10071668 Permanent atrial fibrillation LLT
    22.1 100000004852 10057613 Thromboembolic stroke LLT
    21.1 100000004852 10022754 Intracerebral hemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) AT (Completed) FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-000794-23 Sponsor Protocol Number: 49RC19_0034 Start Date*: 2019-07-26
    Sponsor Name:CHU ANGERS
    Full Title: AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé en simple aveugle comparant les effets neurocognitifs du rivaroxaban par rapport à un antagoniste de la vitamine K
    Medical condition: fibrillation atriale non valvulaire
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10007541 Cardiac disorders SOC
    20.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-000797-30 Sponsor Protocol Number: SPI-IIT-002 Start Date*: 2013-10-08
    Sponsor Name:Department of Medical Research, Odense University Hospital, Svendborg Hospital
    Full Title: Inhibition of aldosterone to diminish diffuse myocardial fibrosis in atrial fibrillation
    Medical condition: Paroxysmal and persistent atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004849 10071667 Persistent atrial fibrillation LLT
    18.1 100000004849 10066664 Recurrent symptomatic atrial fibrillation LLT
    18.1 100000004849 10003661 Atrial fibrillation paroxysmal LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2015-004847-37 Sponsor Protocol Number: EDO-SP-01-2015 Start Date*: 2017-10-05
    Sponsor Name:FONDAZIONE G. D'ANNUNZIO, CHIETI
    Full Title: A pilot study on Edoxaban for the resolution of left atrial thrombosis in patients with non-valvular atrial fibrillation
    Medical condition: Non-Valvular Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10016566 Fibrillation atrial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-003100-13 Sponsor Protocol Number: KKSH-154 Start Date*: 2020-08-03
    Sponsor Name:Martin-Luther-Universität Halle-Wittenberg
    Full Title: Pharmacokinetics of edoxaban in patients with advanced chronic kidney disease (CKD) treated for stroke prevention
    Medical condition: Nonvalvular Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005503-84 Sponsor Protocol Number: AFNET8 Start Date*: 2018-02-14
    Sponsor Name:Kompetenznetz Vorhofflimmern e.V.
    Full Title: A Safety Study Assessing Oral Anticoagulation with Apixaban versus Vitamin-K Antagonists in Patients with Atrial Fibrillation and End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment.
    Medical condition: End-Stage Kidney Disease (ESKD) on Chronic Hemodialysis Treatment and Atrial Fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    23.1 100000004857 10076412 Chronic kidney disease stage 5 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000730-34 Sponsor Protocol Number: ARMYDA-AMULET Start Date*: 2021-06-28
    Sponsor Name:FONDAZIONE TOSCANA GABRIELE MONASTERIO
    Full Title: HeAd-to-head compaRison of single versus dual antiplatelet treatMent strategY after percutaneous left atrial appenDAge closure: A MULticenter, randomizEd sTudy the ARMYDA-AMULET study
    Medical condition: Patients with atrial fibrillation undergoing percutaneous left atrial appendage closure with the Amulet device
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10016566 Fibrillation atrial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2013-003444-24 Sponsor Protocol Number: 1160.189 Start Date*: 2014-11-21
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda.
    Full Title: Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate (110 mg or 150 mg, oral b.i.d.) versus acet...
    Medical condition: A study to compare dabigatran etexilate to acetylsalicylic acid in preventing recurrent stroke for patients that already had a stroke caused by an embolus (clot). Despite testing, it is unknown wh...
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029205 - Nervous system disorders 10067167 Cerebellar embolism PT
    18.1 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    18.1 10029205 - Nervous system disorders 10060839 Embolic cerebral infarction PT
    18.1 10029205 - Nervous system disorders 10074422 Brain stem embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) DE (Completed) BE (Completed) AT (Completed) HU (Completed) IT (Completed) SE (Completed) SI (Completed) ES (Completed) CZ (Completed) SK (Completed) PL (Completed) HR (Completed) GR (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000504-18 Sponsor Protocol Number: A01711 Start Date*: 2011-05-10
    Sponsor Name:Deutsches Herzzentrum München, Klinik für Herz- und Kreislauferkrankungen
    Full Title: DABI-ADP-2: IMPACT OF DABIGATRAN AND PHENPROCOUMON ON CLOPIDOGREL MEDIATED ADP INDUCED PLATELET AGGREGATION IN PATIENTS WITH ATRIAL FIBRILLATION
    Medical condition: Patients with atrial fibrillation and in indication for oral anticoagulation, who are currently receiving additionally clopidogrel for another medical condition, such as acute coronary syndrome and...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10007541 - Cardiac disorders 10068617 Coronary heart disease LLT
    14.1 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    14.1 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    14.1 10047065 - Vascular disorders 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004121-16 Sponsor Protocol Number: AC16141 Start Date*: 2017-09-11
    Sponsor Name:University of Edinburgh
    Full Title: Start or STop Anticoagulants Randomised Trial (SoSTART) after spontaneous intracranial haemorrhage
    Medical condition: Spontaneous Intracranial Haemorrhage (ICH)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10022753 Intracerebral haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-002353-38 Sponsor Protocol Number: OHIRC-20150866 Start Date*: 2017-08-31
    Sponsor Name:Ottawa Heart Institute Research Corporation (OHIRC)
    Full Title: The Optimal Anticoagulation for Enhanced Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial
    Medical condition: risk of stroke by atrial fibrillation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10003658 Atrial fibrillation PT
    22.1 10029205 - Nervous system disorders 10014498 Embolic stroke PT
    20.0 10042613 - Surgical and medical procedures 10059864 Cardiac ablation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 22:05:11 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA